Sam Fazeli

speaker

906 appearances 5 recordings 1 series first heard Oct 2025 last heard 31 Mar

Sam Fazeli’s voice in public audio — every appearance, attributed to the second.

Trend

recordings per month · last 12 months

Recordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.

newest first · ▶ plays the moment

This was Keynote 905.

I think it did have an EV number.

I can't remember.

And which was infortimab vedotin, which is a nectin-4 ADC that now is owned by Pfizer, plus Keytruda pembrolizumab.

Good perioperative regime.

And I think it got lots of claps, et cetera, at the conference because bladder cancer physicians haven't seen data like this in decades.

in cisplatin ineligible patients.

Now this is obviously a more frail and not necessarily the same patient population that was tested in Niagara.

But how do you, is there any way to think about these two trials, Niagara and Keynote 905 together?

What would I take away from making that?

And Susan, quickly, historically, has there been, you know, this continuous conversation about PD-L1 versus PD-1?

Historically, has there been any data that suggests PD-1, PD-L1 are different in the bladder setting?

Oh, no, sorry, sorry, sorry, sorry, sorry, sorry to stop you.

I meant antibody, i.e.

a PD-L1 antibody versus a PD-1 antibody.

Well, so we're going to be all sitting there comparing PCR rates between EVs.

Was it three or four?

Keynote 905 and Volga then.

We look forward to the data.

Sorry, when are we expecting that?

Showing 861–880 of 906 · page 44 of 46